The estrogen and progestin dilemma: new advice, labeling guidelines.
Bren
Linda
L
D001943:Breast Neoplasms / Q000139:chemically induced*; D004338:Drug Combinations; D004348:Drug Labeling; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000592:standards; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects; D005260:Female; D017408:Guidelines as Topic; D006331:Heart Diseases / Q000139:chemically induced*; D019584:Hot Flashes / Q000517:prevention & control; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects; D017698:Postmenopause; D013927:Thrombosis / Q000139:chemically induced*; D014481:United States; D014486:United States Food and Drug Administration
D004338:Drug Combinations; D004966:Estrogens, Conjugated (USP); C466383:Prempro; D017258:Medroxyprogesterone Acetate